Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

April 30, 2011

Study Completion Date

October 31, 2012

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

Bortezomib

Before surgery, an injection of bortezomib is given on days 1, 4, and 8. After surgery, bortezomib is given on days 7 and 21 of each cycle (1 cycle = 28 days).

DRUG

Temozolomide

After surgery, temozolomide is taken by mouth on days 1-7 and 14-21 of each cycle (1 cycle = 28 days).

Trial Locations (1)

60611

Northwestern University, Chicago

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Northwestern University

OTHER